Sarepta Therapeutics, Inc. 8-K

What Happened

• Sarepta Therapeutics, Inc. filed an 8‑K reporting results of its June 4, 2026 annual meeting. Stockholders approved a new 2026 Equity Incentive Plan and a 2026 Employee Stock Purchase Plan; the plans replace the company’s prior plans and provide new share pools for awards and purchases. Class I directors were elected for two‑year terms, an advisory vote on 2025 executive compensation was held, and KPMG LLP was ratified as the company’s independent registered public accounting firm.
• Key counts: as of the April 8, 2026 record date there were 105,571,146 shares outstanding; 82,309,288 shares (77.97%) were present or represented at the meeting.

Key Details

• 2026 Equity Incentive Plan approved: up to 6,286,841 shares of common stock available for awards (subject to adjustments); it supersedes the 2018 plan (as amended).
• 2026 Employee Stock Purchase Plan approved: 1,500,000 shares available for issuance (subject to adjustments); it replaces the prior 2013 ESPP (as amended).
• Directors elected to Class I (two‑year terms): Douglas S. Ingram; Hans Wigzell, M.D., Ph.D.; Kathryn J. Boor, Ph.D.; Michael Chambers; and Deirdre Connelly. Vote totals varied by nominee (e.g., Ingram: 66,812,593 for; Wigzell: 56,984,756 for).
• Advisory "say‑on‑pay" vote: approved on an advisory basis (45,185,398 for; 22,373,065 against). Auditor ratification: KPMG LLP ratified (79,907,368 for; 2,110,136 against).

Why It Matters

• The approved equity and ESPP plans increase the pool of shares available for employee and director awards and employee purchases, which can support recruiting and retention but may have dilution implications for shareholders over time.
• Director elections and auditor ratification confirm the company’s board composition and external audit continuity for governance oversight. The advisory approval of executive compensation clears shareholder approval on pay policy (non‑binding), though the vote showed meaningful opposition that investors may watch going forward.